share
- Mean intraocular pressure (IOP) reduction from washout baseline was 44.6% at 12 months.All patients had IOP with her IOP reduced by more than 20% of his ≤18 mmHg.
- 100% of patients remained off topical IOP-lowering medications.
- All eyes achieved visual acuity of 20/40 or better (BCDVA).
ALISO VIEJO, Calif., April 2, 2024 (Globe Newswire) — SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced its one-year milestone from a first-in-human study of 23 glaucoma patients. Tracking data released. A patient with ocular hypertension who was implanted with his SpyGlass intraocular lens (IOL)-based drug delivery platform containing bimatoprost during cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, April 5-8 in Boston.
One year after implantation, sustained intraocular pressure (IOP) reduction remained consistent across all three dose strengths, with a mean IOP reduction of 44.6% at 12 months compared to preoperative washout baseline levels achieved. All patients maintained an IOP reduction of 20% or more from baseline and an IOP of 18 mmHg or less through month 12. Furthermore, his 100% of patients remained without topical IOP-lowering eye drops. The SpyGlass platform was well tolerated with no product-related adverse events.
“Clinical results one year after transplantation continue to be very encouraging for patients living with glaucoma,” said Margot Goodkin, MD, chief medical officer of SpyGlass Pharma™. “Bimatoprost has been providing safe and highly effective intraocular pressure reduction to patients around the world for over 20 years. These data demonstrate that the SpyGlass Drug Delivery Platform is a game-changer for patients and all cataract surgeons.” It highlights great potential.”
“SpyGlass technology has the potential to change the paradigm and improve the care of glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO of SpyGlass Pharma.TM. “Nearly 5 million cataract surgeries are performed annually in the United States, approximately 20% of which are performed on patients with glaucoma or ocular hypertension. There is a significant unmet need, and SpyGlass is a proven implantable technology. “We are committed to providing safe and effective treatments through our “Improving the Lives of Patients with Chronic Eye Diseases.'' Compelling clinical data released this week shows that we are committed to providing innovative and effective treatments. This suggests that we are on track to provide a comprehensive platform for patients.”
The SpyGlass drug delivery platform containing bimatoprost is designed to deliver bimatoprost to target tissues for three years. Patients will continue to be followed long-term, and the company plans to share long-term data in the coming months. SpyGlass is currently enrolling patients in a Phase I/II trial in the United States to investigate the safety and efficacy of the platform in a larger patient pool. SpyGlass looks forward to working closely with the FDA to advance the program to commercial approval.
About Spyglass Pharma
SpyGlass Pharma was co-founded by Dr. Malik Y. Kahook and Glenn Sussman. The company is focused on developing the world's first IOL-mounted controlled-release drug delivery platform capable of providing multi-year therapy. The technology was originally developed at the Sue Anschutz Rogers Eye Center at the University of Colorado School of Medicine and spun off campus with Series A funding from New Enterprise Associates. http://www.spyglasspharma.com
Media contact:
Claudia Penido
917-763-8733
Cpenido@dna-comms.com